Stoke Therapeutics Inc (STOK)
11.92
+0.23
(+1.97%)
USD |
NASDAQ |
May 03, 10:54
Stoke Therapeutics Price to Book Value: 3.459 for May 3, 2024
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 3.392 |
| May 01, 2024 | 3.355 |
| April 30, 2024 | 3.201 |
| April 29, 2024 | 3.442 |
| April 26, 2024 | 3.601 |
| April 25, 2024 | 3.392 |
| April 24, 2024 | 3.384 |
| April 23, 2024 | 3.265 |
| April 22, 2024 | 3.265 |
| April 19, 2024 | 3.497 |
| April 18, 2024 | 3.381 |
| April 17, 2024 | 3.401 |
| April 16, 2024 | 3.613 |
| April 15, 2024 | 3.543 |
| April 12, 2024 | 3.706 |
| April 11, 2024 | 3.918 |
| April 10, 2024 | 3.703 |
| April 09, 2024 | 3.729 |
| April 08, 2024 | 3.772 |
| April 05, 2024 | 3.648 |
| April 04, 2024 | 3.532 |
| April 03, 2024 | 3.719 |
| April 02, 2024 | 3.796 |
| April 01, 2024 | 3.915 |
| March 28, 2024 | 3.918 |
| Date | Value |
|---|---|
| March 27, 2024 | 4.112 |
| March 26, 2024 | 2.986 |
| March 25, 2024 | 1.886 |
| March 22, 2024 | 1.828 |
| March 21, 2024 | 1.738 |
| March 20, 2024 | 1.738 |
| March 19, 2024 | 1.683 |
| March 18, 2024 | 1.764 |
| March 15, 2024 | 1.854 |
| March 14, 2024 | 1.865 |
| March 13, 2024 | 1.971 |
| March 12, 2024 | 1.908 |
| March 11, 2024 | 2.078 |
| March 08, 2024 | 2.178 |
| March 07, 2024 | 2.201 |
| March 06, 2024 | 2.294 |
| March 05, 2024 | 2.052 |
| March 04, 2024 | 1.973 |
| March 01, 2024 | 2.196 |
| February 29, 2024 | 2.227 |
| February 28, 2024 | 2.291 |
| February 27, 2024 | 2.351 |
| February 26, 2024 | 1.914 |
| February 23, 2024 | 1.709 |
| February 22, 2024 | 1.531 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
0.8628
Minimum
Oct 27 2023
11.51
Maximum
Dec 21 2020
3.541
Average
3.37
Median
Price to Book Value Benchmarks
| NeuBase Therapeutics Inc | 0.1682 |
| iBio Inc | 0.7956 |
| Actinium Pharmaceuticals Inc | 5.997 |
| Lixte Biotechnology Holdings Inc | 13.55 |
| Fate Therapeutics Inc | 1.123 |
Price to Book Value Related Metrics
| PS Ratio | 59.72 |
| Price | 11.92 |
| Earnings Yield | -19.88% |
| Market Cap | 551.94M |